Get the Stockscreener App
0.901
5.16%
-0.049
After Hours:
.93
0.029
+3.22%
Oncolytics Biotech Inc stock is traded at $0.901, with a volume of 861.55K.
It is down -5.16% in the last 24 hours and down -15.79% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.95
Open:
$0.95
24h Volume:
861.55K
Relative Volume:
0.69
Market Cap:
$96.95M
Revenue:
-
Net Income/Loss:
$-25.30M
P/E Ratio:
-3.2064
EPS:
-0.281
Net Cash Flow:
$-18.79M
1W Performance:
-7.96%
1M Performance:
-15.79%
6M Performance:
-30.16%
1Y Performance:
+44.55%
1-Day Range:
$0.901
$0.9599
1-Week Range:
$0.901
$1.00
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.901 | 102.23M | 0 | -25.30M | -18.79M | -0.281 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Aug Closing: Is Oncolytics Biotech Inc stock a good dividend stock2026 Setups & Free Long-Term Investment Growth Plans - baoquankhu1.vn
If You Invested $1,000 in Oncolytics Biotech Inc (ONCY) - Stock Titan
Oncolytics Biotech Inc. Adopts New Articles and Notice of Articles Following Continuance to British Columbia Corporate Law - Minichart
Oncolytics Biotech completes first step of redomestication to British Columbia - Investing.com UK
Oncolytics Biotech completes first step of redomestication to British Columbia By Investing.com - Investing.com India
Form 8K Oncolytics Biotech Inc. For: 20 March By Investing.com - Investing.com South Africa
Form 8K Oncolytics Biotech Inc. For: 20 March - Investing.com
Oncolytics Biotech Shifts Corporate Domicile to British Columbia - TipRanks
Oncolytics Biotech (NASDAQ: ONCY) outlines move from Canada to Nevada - Stock Titan
Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - marketscreener.com
Oncolytics Biotech Shares Gain on Upcoming Clinical Data Presentations - AD HOC NEWS
Oncolytics Biotech® to Host Conference Call to Discuss Second Qu - GuruFocus
Oncolytics Biotech Showcases Pelareorep as Immune-Priming Backbone With New AACR 2026 Data - TipRanks
Oncolytics to present new data on Pelareorep at AACR 2026 - TipRanks
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - marketscreener.com
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
Oncolytics (ONCY) Presents Promising Cancer Research at AACR 202 - GuruFocus
Oncolytics Highlights New Pelareorep Data in Cancer Immunotherapy - TipRanks
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026 - The Manila Times
Oncolytics Biotech (Nasdaq: ONCY) showcases new pelareorep immune-priming data at AACR 2026 - Stock Titan
Pancreatic cancer signal, breast tumor immune data put Oncolytics at AACR - Stock Titan
Oncolytics Biotech Inc. (ONCY) Competitors - Meyka
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Is It Time To Reconsider Oncolytics Biotech (ONCY) After A Huge DCF Valuation Gap? - simplywall.st
Growth Report: What is Oncolytics Biotech Incs market position2026 Growth vs Value & Fast Entry Momentum Alerts - baoquankhu1.vn
Insider Buying: James Parsons Acquires Additional Shares of Onco - GuruFocus
Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) Director Purchases 10,000 Shares of Stock - MarketBeat
Insider Buying: James Parsons Acquires Additional Shares of Oncolytics Biotech Inc (ONCY) - GuruFocus
Oncolytics Biotech (ONCY) director adds 10,000 common shares - Stock Titan
Oncolytics Biotech (ONCY) CEO buys 5,050 common shares at $0.96 - Stock Titan
ONCY SEC FilingsOncolytics Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
What is Oncolytics Biotech Incs 5 year growth outlookProduct Launch & Verified Swing Trading Watchlists - baoquankhu1.vn
How Oncolytics Biotech Inc. stock compares to market leadersProfit Target & Step-by-Step Swing Trade Plans - Naître et grandir
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types - marketscreener.com
Oncolytics Biotech Advances Pelareorep Into New Phase 2 Colorectal Cancer Study - TipRanks
Cancer Treatment Breakthroughs Stack Up as Clinical Pipelines Advance - Baystreet.ca
Earnings Report: Is Oncolytics Biotech Inc undervalued by DCF analysisJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion - Cantech Letter
Oncolytics Biotech Launches Randomized Phase 2 REO-033 Trial for Pelareorep in RAS-Mutant MSS Metastatic Colorectal Cancer — With FDA Fast Track Behind It - Oncodaily
Oncolytics launches phase 2 colorectal cancer study REO 033 By Investing.com - Investing.com Canada
Oncolytics launches phase 2 colorectal cancer study REO 033 - Investing.com
Oncolytics Biotech Launches Phase 2 Colorectal Cancer Trial - TipRanks
Oncolytics Biotech Launches Randomized Colorectal Cancer Study - Bitget
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics Biotech (NASDAQ: ONCY) launches Phase 2 pelareorep colorectal cancer study - Stock Titan
Oncolytics Biotech Inc initiates phase 2 study for metastatic colorectal cancer - marketscreener.com
Oncolytics (ONCY) Initiates Phase 2 Trial for Metastatic Colorec - GuruFocus
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study - The Manila Times
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):